Zemler / Shutterstock.com
A decision by the CJEU on a Latvian case should make it easier in the future to challenge an MA granted for a generic version of a reference product, as Trevor Cook of WilmerHale explains.
Since the EU regime of data exclusivity for pharmaceuticals was amended in late 2005, in large part to reflect Court of Justice of the EU (CJEU) case law in the 1990s and early 2000s, there has been little case law on the interpretation of the new legislation. This situation is now starting to change.
In order to secure a marketing authorisation (MA) for a new medicinal product, in addition to demonstrating satisfactory quality, applicants must file extensive clinical and non-clinical data to support its safety and efficacy in accordance with article 8(3)(i) of Directive 2001/83/EC, as amended by Directive 2004/27/EC.
According to article 10, an application for a generic MA of a medicinal product previously authorised under article 8 can be sought eight years after the first MA in the EU for the active substance in the ‘reference medicinal product’, but such a generic MA cannot take effect until ten years after the first MA for the active substance.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
CJEU; pharmaceuticals